Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy
Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy
复制标题
肿瘤突变负荷与肿瘤负荷比及抗PD-1/PD-L1免疫治疗临床获益的预测
DOI：
10.1016/j.mehy.2018.05.005
复制
发表时间：
2018-07-01
影响因子：
4.7
通讯作者：
Zang, Yuan-Sheng
中科院分区：
文献类型：
--
作者：
Qin, Bao-Dong;Jiao, Xiao-Dong;Zang, Yuan-Sheng
免疫检查点抑制剂已经深刻地改变了几种恶性肿瘤的治疗前景。建立检查点阻断的预测性生物标志物对于鉴定可能对免疫疗法有良好反应的人群和最大化治疗益处具有相当重要的意义。一些试验表明，肿瘤突变负荷（TMB）可以预测对免疫治疗的反应，但在具有高TMB的癌症中也观察到一些较低的临床益处。免疫应答强度和治疗前肿瘤负荷（TB）之间的不平衡也可能导致癌症患者的免疫治疗失败。出于这个原因，我们假设TMB-TB比率可以预测检查点抑制剂免疫治疗的临床获益，并且PFS或ORR应该在TMB-TB比率高的患者中比在TMB-TB比率低的个体中更经常使用。
Immune checkpoint inhibitors have profoundly altered the therapeutic landscape of several malignancies. The establishment of predictive biomarkers for checkpoint blockades is of the considerable importance in the identification of populations likely to experience a good response to immunotherapy and to maximize the therapeutic benefits. Several trials showed that the tumor mutation burden (TMB) could predict the response to immunotherapy, but some lower clinical benefit was also seen in cancer with high TMB. The imbalance between the strength of immune response and pretreatment tumor burden (TB) could also cause immunotherapy to fail in cancer patients. For this reason, we hypothesized that the TMB-TB ratio could predict the clinical benefit of checkpoint inhibitor immunotherapy and that PFS or ORRs should be used more often in patients with high TMB-TB ratio than in individuals with low TMB-TB ratios.